Donald Kennedy, the edior-in-chief of Science, yesterday wrote an editorial about a legal dispute between the New England Journal of Medicine and the drug company Pfizer. Pfizer wants the NEJM to provide the reviewer comments on submitted papers about the two Pfizer products celecoxib (Celebrex) and valdecoxib (Bextra). Both drugs are used to treat pain and belong to the COX-2 inhibitor class of drugs.